The therapeutic community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to deliver a more substantial loss in